Evidence map›Paper›PMID 35226425›Full record

ArticleJournal of Korean medical science2022

Kinetics of Neutralizing Antibody Responses Against SARS-CoV-2 Delta Variant in Patients Infected at the Beginning of the Pandemic.

Pyoeng Gyun Choe, Yuri Kim, Euijin Chang, Chang Kyung Kang, Nam Joong Kim, Nam-Hyuk Cho, Wan Beom Park, Myoung-Don Oh

Open access · goldAbstract read
In one paragraph

Article in Journal of Korean medical science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Pyoeng Gyun Choe *Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0001-6794-7918
Yuri Kim *Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-9385-2557
Euijin ChangDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0001-7417-0318
Chang Kyung KangDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0003-1952-072X
Nam Joong KimDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0001-6793-9467
Nam-Hyuk ChoDepartment of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, Korea. chonh@snu.ac.kr.ORCID https://orcid.org/0000-0003-3673-6397
Wan Beom ParkDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. wbpark1@snu.ac.kr.ORCID https://orcid.org/0000-0003-0022-9625
Myoung-Don OhDepartment of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-2344-7695
Seoul National University · KR

Funding

National Research Foundation of Korea 2021M3A9H5020761National Research Foundation of Korea 2021M3A9I2080498Seoul National University Hospital 04-2021-0210
6 · The paper itself

Abstract

We investigated the kinetics of the neutralizing antibody responses to the severe acute respiratory syndrome-coronavirus-2 delta variant over the course of 1 year in 16 patients infected at the beginning of the pandemic. In patients with severe disease, neutralizing responses to the delta variant were detectable, albeit at lower levels than responses to the wild type. Neutralizing responses to the delta variant were undetectable, however, in asymptomatic persons. This finding implies that the vaccination strategy for persons with past natural infection should depend on the severity of the previous infection.

Indexed as

AdultAgedAntibodies, NeutralizingAntibodies, ViralCOVID-19COVID-19 VaccinesFemaleHumansKineticsMaleMiddle AgedSARS-CoV-2Severity of Illness IndexVaccinationYoung AdultAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesCOVID-19Delta VariantFRNTSARS-CoV-2

Identifiers

PMID35226425
PMCPMC8885454
OpenAlexW4213192726

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.